{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 440816974
| IUPAC_name = (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
| image = Naloxone.svg
| image2 = Naloxone-3D-balls.png

<!--Clinical data-->
| tradename = Narcan, Evzio
| Drugs.com = {{drugs.com|monograph|naloxone-hydrochloride}}
| pregnancy_AU = B1
| pregnancy_US = C

| pregnancy_US_comment =<ref name="AHFS2015">{{웹 인용|title=Naloxone Hydrochloride|url=https://www.drugs.com/monograph/naloxone-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|access-date=2 January 2015|url-status=live|archive-url=https://web.archive.org/web/20150102115454/http://www.drugs.com/monograph/naloxone-hydrochloride.html|archive-date=2 January 2015}}</ref>
| legal_AU = S3
| legal_AU_comment =<ref>{{웹 인용 | url=https://www.theguardian.com/society/2016/jan/29/selling-opioid-overdose-antidote-naloxone-over-counter-will-save-lives | title=Selling opioid overdose antidote Naloxone over counter 'will save lives' | publisher=The Guardian | date=29 January 2016 | author=Melissa Davey}}</ref>
| legal_UK = POM
| routes_of_administration = 기관 내 투입, 비강 내 투입, 수액 요법 및, [[근육 주사]]

<!--Pharmacokinetic data-->
| bioavailability = 2% (구강, 90%가 흡수되지만, 높은 초회통과를 가진다)
| metabolism = [[간장]]
| onset       = 2 분 (IV), 5 분 (IM)<ref name=AHFS2015/>
| elimination_half-life = 1–1.5 시간
| duration_of_action= 30에서 60 분<ref name=AHFS2015/>
| excretion = 소변, 담즙

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 465-65-6
| ATC_prefix = A06
| ATC_suffix = AH04
| ATC_supplemental = <br/>{{ATC|V03|AB15}}
| PubChem = 5284596
| IUPHAR_ligand = 1638
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01183
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4447644
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 36B82AMQ7N
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08249
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 7459
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 80

<!--Chemical data-->
| C=19 | H=21 | N=1 | O=4
| molecular_weight = 
| smiles = O=C1[C@@H]2OC3=C(O)C=CC4=C3[C@@]2([C@]5(CC1)O)CCN(CC=C)[C@@H]5C4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UZHSEJADLWPNLE-GRGSLBFTSA-N
| synonyms = <small>17-allyl- 4,5α-epoxy- 3,14-dihydroxymorphinan- 6-one</small>
|drug_name=|alt=|caption=|type=|MedlinePlus=|legal_status=|licence_EU=|pregnancy_category=|licence_US=|legal_US=Rx only}}

'''날록손'''(Naloxone)은 1960년도에 Sankyo사가 개발한<ref>US Patent 3254088 - Morphine Derivative</ref> [[아편]][[길항제]]이다.<ref>{{저널 인용 |author=Sirohi, S; Dighe, SV; Madia, PA; Yoburn, BC |제목=The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity |journal=Journal of Pharmacology and Experimental Therapeutics |volume=330 |issue=2 |pages=513–9 |year=2009 |month=August |pmid=19435929 |pmc=2713087  |url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713087/ |doi=10.1124/jpet.109.152678}}</ref> 날록손은 아편계약의 [[과다복용]]에 반대작용을 위해 사용되는 약이다. 날록손은 특히 생명을 위협하는 중추신경계와 호흡계의 우울증에 효과가 있다. 날록손은 또한 실험적으로 '선천적 발한 통증 무감각증'(congenital insensitivity to pain with anhidrosis, CIPA)(매우 흔하지 않은 질병 (1/1억2천5백만) 통증을 느끼지 못함)에 사용한다.

== 각주 ==
<references/>

[[분류:세계 보건 기구 필수 의약품]]
[[분류:케톤]]
[[분류:알코올]]
[[분류:알켄]]
[[분류:페놀 에터]]
[[분류:삼차 알코올]]
[[분류:카파 오피오이드 수용체 대항제]]
[[분류:응급용 화학 물질]]
[[분류:4,5-에폭시모르피난]]